The current study was the first of its kind to explore the potential clinical role of SPEF1 and SPEF2 in BLCA, building upon previous research that identified these proteins in other cancers and potentially premalignant lesions. This evidence concerns the gene SPEF1 and bladder transitional cell carcinoma.